<DOC>
	<DOCNO>NCT00192803</DOCNO>
	<brief_summary>This feasibility study design examine modulation relative activity ACE ACE2 diabetic patient follow treatment angiotensin type 1 receptor ( AT1R ) antagonist , Candesartan . This study provide close insight possible involvement renin-angiotensin system ( RAS ) -related enzymatic component development attenuation vascular pathogenesis .</brief_summary>
	<brief_title>Non-Insulin Dependent Diabetes Mellitus ( NIDDM ) Angiotensin Converting Enzyme 2 ( ACE2 ) : Diabetic Patients Treated With Antihypertensive Drugs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Signed informed consent Nonsmokers Type II DM diagnose patient Blood pressure &lt; 135/90 Serum HbA1C &gt; 7 % Serum creatinine &lt; 1mg % Urine microalbumin &lt; 300 mg/day Body mass index ( BMI ) &lt; 35 kg/m2 Insulindependent diabetic patient Patient persistent microalbuminuria Patient history severe hypertension Congestive heart failure Patient receive reninangiotensinaldosterone system ( RAAS ) relate antihypertensive medication . Patient major hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>niddm</keyword>
	<keyword>ace2</keyword>
	<keyword>NIDDM patient</keyword>
</DOC>